Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?

Introduction Treatment options for metastatic renal cell carcinoma disease have been improved in recent years. However, there is still no optimal treatment sequence or combination for metastatic disease. We aimed to investigate whether patients differed in terms of disease outcomes regarding pre-niv...

Full description

Saved in:
Bibliographic Details
Published in:Cureus
Main Authors: Ucar, Gokhan, Acikgoz, Yusuf, Ergun, Yakup, Bal, Oznur, Yilmaz, Mesut, Karakaya, Serdar, Akdeniz, Nadiye, Kostek, Osman, Aydin Isak, Ozlem, Yazici Sener, Gorkem, Dirikoc, Merve, Aktürk Esen, Selin, Dogan, Mutlu, Uncu, Dogan
Format: Artigo
Language:Inglês
Published: Cureus 2020
Subjects:
Radiation Oncology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574822/
https://ncbi.nlm.nih.gov/pubmed/33094066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.10525
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items